Literature DB >> 11077094

Nerve rootlets to be sectioned for spasticity resolution in selective dorsal rhizotomy.

T Fukuhara1, I M Najm, K H Levin, M G Luciano, C L Brant M S.   

Abstract

BACKGROUND: The goal of this study is to confirm the efficacy of the protocol for selective dorsal rhizotomy (SDR). In this protocol, rootlets to be sectioned are selected by palpable responses elicited by intraoperative electrical stimulation, without detailed electromyographic classifications.
METHODS: Thirty-six children with spasticity due to cerebral palsy underwent SDR according to our protocol. Priority was given to sectioning rootlets that showed palpable clonic or bilateral responses, which were considered abnormal, over sectioning rootlets that merely had hyperactive responses to intraoperative stimulation. The results of intraoperative monitoring and sectioning amount were analyzed by physical evaluation.
RESULTS: Significant improvements were obtained in passive range of motion and muscle tone of the lower extremities. The total percentages of rootlets with abnormal and hyperactive responses at L3 and S1 were bilaterally correlated with preoperative spasticity of the hip adductors and the plantar flexors, respectively. When rootlets with hyperactive responses were excluded from the correlation analysis, no bilateral correlation was observed. From the correlation analyses between the improvement in the physical evaluation and the amount of nerve sectioned, it was concluded that a greater improvement in muscle tone in all examined muscles, except the hamstrings, could be obtained if larger amounts of nerve roots were sectioned.
CONCLUSION: The number of rootlets with palpable abnormal and hyperactive responses elicited by intraoperative stimulation reflects the preoperative spasticity of multiple muscles. This implies that only selecting rootlets with palpable responses can be reliable. Because more sectioning leads to better spasticity resolution, our protocol should be reviewed to increase the percentage of rootlets sectioned with hyperactive responses, especially for innervated levels of severely affected muscles.

Entities:  

Mesh:

Year:  2000        PMID: 11077094     DOI: 10.1016/s0090-3019(00)00282-2

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  7 in total

Review 1.  Lumbosacral Dorsal Rhizotomy for Spastic Cerebral Palsy: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-07-06

2.  Peripheral sensory neuropathy observed in children with cerebral palsy: is chronic afferent excitation from muscle spindles a possible cause?

Authors:  Toru Fukuhara; Yoichiro Namba; Ichiro Yamadori
Journal:  Childs Nerv Syst       Date:  2010-03-09       Impact factor: 1.475

3.  Histological evidence of intraoperative monitoring efficacy in selective dorsal rhizotomy.

Authors:  Toru Fukuhara; Daisuke Nakatsu; Yoichiro Namba; Ichiro Yamadori
Journal:  Childs Nerv Syst       Date:  2011-04-19       Impact factor: 1.475

4.  Functional posterior rhizotomy: the Tokyo experience.

Authors:  Nobuhito Morota
Journal:  Childs Nerv Syst       Date:  2007-07-26       Impact factor: 1.475

Review 5.  Selective dorsal rhizotomies in the treatment of spasticity related to cerebral palsy.

Authors:  Jean-Pierre Farmer; Abdulrahman J Sabbagh
Journal:  Childs Nerv Syst       Date:  2007-07-21       Impact factor: 1.475

6.  Frequency distribution in intraoperative stimulation-evoked EMG responses during selective dorsal rhizotomy in children with cerebral palsy-part 1: clinical setting and neurophysiological procedure.

Authors:  Simone Wolter; Claudia Spies; John H Martin; Matthias Schulz; Akosua Sarpong-Bengelsdorf; Joachim Unger; Ulrich-W Thomale; Theodor Michael; James F Murphy; Hannes Haberl
Journal:  Childs Nerv Syst       Date:  2020-06-23       Impact factor: 1.475

Review 7.  Neurosurgical Management of Childhood Spasticity: Functional Posterior Rhizotomy and Intrathecal Baclofen Infusion Therapy.

Authors:  Nobuhito Morota; Satoshi Ihara; Hideki Ogiwara
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-07-31       Impact factor: 1.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.